VANCOUVER, British Columbia, Dec. 19, 2018 (GLOBE NEWSWIRE) — Agraflora Organics All-embracing Inc. (CSE: AGRA) (Frankfurt: PU31) (OTCPK: PUFXF) (formerly PUF Ventures Inc.) appear a three date timeline aftermost anniversary for the retrofitting of their new greenhouse ability in Delta, BC. What they did not broadcast to the accessible at the time, however, is that this 2.2 actor aboveboard bottom ability in Delta now represents the added better cannabis greenhouse ability in Canada (among those that are currently physically built). AGRA’s Delta ability is added in admeasurement abandoned to the Smiths Falls ability endemic by Canopy Advance Corp., the world’s better cannabis company, and it is beyond than the added two better cannabis accessories in Canada. AGRA’s Delta greenhouse is 100,000 aboveboard anxiety beyond than Aurora Cannabis Inc.’s ability in Edmonton, and it is additionally added than 700,000 aboveboard anxiety beyond than the accustomed admeasurement of the Leamington ability endemic by Aphria Inc.
With this abundant aboveboard footage, of course, additionally comes the abeyant for cogent bulb advance and sales. According to AGRA CEO Derek Ivany, the ability in Delta will be able of bearing “…approximately 0.12 kg [of cannabis flower] per aboveboard foot,” acceptance it to avowal an anniversary assembly accommodation of 250 actor grams of high-quality cannabis product, and AGRA has already caked offtake agreements with two above cannabis organizations in Canada in adjustment to accommodate themselves with abeyant approaching sales outlets. AGRA became allotment of Canopy Advance Corp’s CraftGrow Family in 2017, and, in an advertisement appear this accomplished Thursday, AGRA declared that Namaste Technologies, through its wholly-owned accessory Cannmart Inc, will accept the appropriate of aboriginal abnegation on the acquirement of up to 25,000,000 grams of cannabis from AGRA at a amount of $4.00 per gram. The Namaste adjustment abandoned represents up to $100 actor in abeyant approaching acquirement for AGRA.
The greenhouse in Delta was anchored through a affiliation with the Houweling’s Group, and it is this affiliation that will additionally admonition AGRA both aerate the growing abeyant of the ability and ensure that it is up and active on schedule. The Houweling’s Groups brings forty years of greenhouse acquaintance and growing ability to the activity as able-bodied as a deluge of accustomed infrastructure. The Houweling’s Group is a absolutely angular chip alignment with a absolute of 8.4 actor aboveboard anxiety of greenhouse amplitude in Canada and the United States and added than 200 employees. They accept agent groups alive in growing, harvesting, distribution, administration, I.T. and finance, and this agency that they are absolutely self-sufficient.
In adjustment to armamentarium AGRA’s affairs for retrofitting the greenhouse in Delta, AGRA has anchored addition $7.5 actor in costs from the Delta Organic Cannabis Corp. (DOCC). In September of 2018 AGRA entered into a $40-million disinterestedness accord and earn-in acceding with DOCC, a abreast captivated Toronto-based advance aggregation managed by some of Canada’s arch cannabis investors, and so far $20-million of this money has already been provided. On October 18th, an antecedent tranche of $12.5 actor was secured, while the best contempo $7.5 actor came through on December 10th. Both tranches were purchased at a allotment amount of about 45 cents.
As declared previously, AGRA will be retrofitting their Delta greenhouse in three stages, aiming to accomplish the ability absolutely operational by 2021. The aboriginal date will accommodate the achievement of 350,000 aboveboard anxiety of growing amplitude and 100,000 aboveboard anxiety of column assembly accessories and is appointed to be completed in the added division of 2019. The added date will accommodate an added 1.45 actor aboveboard anxiety to be completed by the fourth division of 2019. Finally, addition 400,000 aboveboard anxiety of amplitude will be completed by the end of 2020.
With all of these aspects combined, AGRA has placed themselves in an enviable position aural the Canadian cannabis industry. Not abandoned does the aggregation accept one of the top three better cannabis greenhouses in the country, but they additionally accept the financing, expertise, infrastructure, and sales outlets bare to aerate the abeyant of the project.
About Agraflora Organics All-embracing Inc.
Agraflora Organics All-embracing is a growth-oriented and adapted aggregation focused on the all-embracing cannabis industry. It has buying in several cannabis companies, including AAA Heidelberg Inc. and Propagation Casework Canada in Canada, and is actively advancing added opportunities aural the cannabis industry. Agraflora Organics has an advantage to acquirement 100 percent of AAA Heidelberg, a accountant ambassador beneath the Access to Cannabis for Medical Purposes Regulations.
ON BEHALF OF THE BOARD OF DIRECTORS
Derek Ivany, President & CEO
For added information:
AgraFlora Organics All-embracing Inc.
E: Media (800) 783-6056
No banal barter or balance authoritative ascendancy has advised or accustomed albatross for the capability or accurateness of this release. Some of the statements independent in this absolution are advanced statements, such as estimates and statements that call the Issuer’s approaching plans, objectives or goals, including words to the aftereffect that the Issuer or administration expects a declared action or aftereffect to occur. Since advanced statements abode approaching contest and conditions, by their actual nature, they absorb inherent risks and uncertainties.
Global Objective Marketing
This allotment was accounting and broadcast by Global Objective Marketing (GOM). All of the admonition independent aural was produced application about accessible admonition and any opinions about individuals, companies or industries bidding aural this absolution accord abandoned to GOM. The opinions bidding by GOM should not be advised as complete, accurate, or accustomed advance advice. Any advance decisions fabricated by readers are endemic and endemic alone. To ensure that you are authoritative advance decisions that serve your own best interests, we acclaim that you advance the casework of a able banking artist or advisor. In adjustment to accede with Section 17(b) of the 1933 Balance Act, GOM discloses that it was paid a sum of fifteen-hundred CAD to address this agreeable for AgraFlora Organics International.
PEDMARKTM is proposed to be adumbrated for the blockage of ototoxicity induced by cisplatin chemotherapy in patients 1 ages to < 18 years of age with localized, non-metastatic, solid tumors.
RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty biologic company, afterward a pre-submission affair with the oncology analysis of the U.S. Food and Biologic Administration (FDA), has accomplished a rolling New Biologic Appliance (NDA) for PEDMARKTM (a altered conception of sodium thiosulfate (STS) to be administered by infusion) for the blockage of ototoxicity induced by cisplatin chemotherapy in patients 1 ages to < 18 years of age with localized, non-metastatic, solid tumors. The Aggregation is targeting U.S. approval of PEDMARKTM in the additional bisected of 2019. PEDMARKTM has been accustomed Orphan Drug, Breakthrough Analysis and Fast Track designations from the FDA.
“We accept that PEDMARKTM has the abeyant to abode the analytical unmet charge to anticipate or decidedly abate cisplatin induced audition accident of abounding accouchement with localized solid tumors, area the all-embracing adaptation ante are aerial and affection of activity is paramount,” said Rosty Raykov, Chief Executive Officer of Fennec. “The admission of the rolling NDA acquiescence for PEDMARKTM is a above achievement, as it marks the aboriginal anytime appliance for authoritative approval of a biologic for blockage of audition loss. We are accustomed to accept collaborated over a decade with Oregon Health and Science University (OHSU), Accouchement Oncology Accumulation (COG) and SIOP alarmist accumulation (SIOPEL) bearing convenance alteration after-effects that underlie this application. Fennec will assignment agilely to complete the acquiescence abutting year.”
In Europe, Fennec intends to abide its Business Authorisation Appliance (MAA) via the European Medicines Agency’s Paediatric-use business authorisation (PUMA) alleyway abutting year. This is accurate by the Paediatric Committee (PDCO) afresh accustomed Paediatric Investigation Plan (PIP).
About PEDMARKTM and ototoxicity
Cisplatin and added platinum compounds are basic chemotherapeutic apparatus for abounding pediatric malignancies. Unfortunately, platinum-based therapies account ototoxicity in abounding patients, and are decidedly adverse to the survivors of pediatric cancer.
Each year in the U.S. and Europe there is estimated that over 10,000 accouchement with solid tumors are advised with platinum agents. The all-inclusive majority of these anew diagnosed tumors are localized and classified as low to average accident in nature. These localized cancers may accept all-embracing adaptation ante of greater than 80%, added emphasizing the accent of affection of activity afterwards treatment. The accident of audition accident in these accouchement depends aloft the dosage and continuance of chemotherapy, and abounding of these accouchement crave constant audition aids. There is currently no accustomed antitoxin abettor for this audition accident and alone expensive, technically difficult and sub-optimal circling (inner ear) implants accept been apparent to accommodate some benefit. Infants and adolescent accouchement at analytical stages of development abridgement accent accent development and literacy, and earlier accouchement and adolescents abridgement social-emotional development and educational achievement.
PEDMARKTM has been advised by accommodating groups in two Phase 3 analytic studies of adaptation and abridgement of ototoxicity: COG ACCL0431 and SIOPEL 6. Both studies are complete. COG ACCL0431 enrolled one of bristles adolescence cancers about advised with accelerated cisplatin analysis for localized and broadcast disease, including anew diagnosed hepatoblastoma, antibody corpuscle tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled alone hepatoblastoma patients with localized tumors. COG ACCL0431 final after-effects were appear in the Lancet Oncology. SIOPEL 6 final after-effects were appear in the New England Journal of Medicine.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., is a specialty biologic aggregation focused on the development of PEDMARKTM (a altered conception of sodium thiosulfate (STS)) for the blockage of platinum-induced ototoxicity in pediatric patients. STS has accustomed Orphan Biologic Designation in the US in this setting. Further, PEDMARKTM received Breakthrough Analysis and Fast Track Designation by the FDA in March 2018. In Europe PEDMARKTM has been accustomed by the EMA for Business Authorization Appliance acquiescence via the PUMA alleyway which if accustomed affords Fennec ten years authoritative exclusivity for the product. Fennec has a authorization acceding with Oregon Health and Science University (OHSU) for absolute common authorization rights to bookish acreage directed to STS and its use for chemoprotection, including the blockage of ototoxicity induced by platinum chemotherapy, in humans. For added information, amuse appointment Media
Forward Looking Statements
Except for absolute advice declared in this columnist release, all added statements are forward-looking. Advanced statements are accountable to assertive risks and uncertainties inherent in the Company’s business that could account absolute after-effects to vary, including such risks that authoritative and guideline developments may change, accurate abstracts may not be acceptable to accommodated authoritative standards or cancellation of appropriate authoritative clearances or approvals, analytic after-effects may not be replicated in absolute accommodating settings, aegis offered by the Company’s patents and apparent applications may be challenged, invalidated or baffled by its competitors, the accessible bazaar for the Company’s articles will not be as ample as expected, the Company’s articles will not be able to access one or added targeted markets, revenues will not be acceptable to armamentarium added development and analytic studies, the Aggregation may not accommodated its approaching basic requirements in altered countries and municipalities, and added risks abundant from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year concluded December 31, 2017. Fennec Pharmaceuticals, Inc. disclaims any obligation to amend these advanced statements except as appropriate by law.
The accurate advice discussed in this account absolution accompanying to PEDMARKTM is basic and investigative. Such artefact candidates are not accustomed by the U.S. Food and Biologic Administration, Health Canada or added authoritative and no abstracts can or should be fatigued apropos the assurance or capability of such artefact candidate.
For a added abundant altercation of accompanying accident factors, amuse accredit to our accessible filings accessible at www.sec.gov and Media
For added information, amuse contact:
Chief Executive Officer
Fennec Pharmaceuticals Inc.
T: (919) 636-5144